Overview
Joseph Mossel is co-founder, president, and general manager for the United States at Ibex Medical Analytics, a company transforming cancer diagnostics with AI since 2016 per the about page. Ibex set out to transform pathology by ensuring every patient can receive an accurate, timely, and personalized cancer diagnosis. Today Ibex is by far the most widely deployed artificial intelligence platform in pathology per company materials.
Ibex solutions serve leading physicians, healthcare organizations, and diagnostic providers — supporting detection, grading, and classification of breast, prostate, lung, and gastric cancers for both H&E and IHC staining.
Role and company
As Co-founder, President and GM U.S., Mossel leads American commercial operations alongside CEO Yair Heller and co-founder CTO Chaim Linhart, PhD. Mossel also serves as board member per Ibex leadership page. Ibex partners with top pharma organizations for AI-powered IHC biomarker quantification through its Biopharma offering built on clinical leadership and technical excellence.
Developed by pathologists for pathologists, Ibex raises physician confidence, streamlines diagnostic workflows, and enables better clinical outcomes per about page mission statement.
Background and career context
Ibex about page establishes Mossel as co-founder, president, and GM U.S. without listing prior employers on the cited page reviewed July 2026. His public identity is tied to pathology AI commercialization in the United States — the largest diagnostics market for digital pathology adoption.
Mossel’s board role alongside operational U.S. leadership gives him governance and go-to-market authority in Ibex’s primary growth geography outside Israel headquarters.
Company-building or leadership context
Mossel co-founded Ibex in 2016 with a pathologist-centric development philosophy — algorithms trained and validated with practicing pathologists rather than pure computer vision teams disconnected from diagnostic liability. Ibex expanded from initial deployments to worldwide field-proven AI detecting multiple cancer types across H&E and IHC workflows.
Biopharma IHC quantification partnerships extend Ibex beyond clinical diagnostics into pharmaceutical trial biomarker scoring — diversifying revenue under Mossel’s U.S. commercial leadership.
Public milestones
2016: Ibex founded; leading AI-powered pathology per about page. Ibex reports widest deployment among pathology AI platforms on ibex-ai.com reviewed 2026. Mossel listed Co-founder, President and GM, U.S. and Board Member on leadership roster.
Ibex touches lives of patients worldwide daily per company about statement — scale claim tied to deployment breadth across health systems and diagnostic labs.
Why their work matters
Ibex under Mossel’s co-founding leadership proves pathology AI can achieve widest global deployment when built with pathologist workflow input and supports both clinical diagnostics and pharma biomarker quantification. Cancer diagnostic accuracy and turnaround time improvements directly affect treatment staging decisions — high-stakes outcomes unlike administrative AI categories.
For healthcare AI readers, Ibex is digital pathology AI — distinct from radiology CAD vendors like Aidoc but sharing regulated diagnostic evidence requirements.
Sources and references
Primary sourcing: Ibex Medical Analytics About page, reviewed July 10, 2026.
- Ibex — About (ibex-ai.com)
Founded 2016 per about page. Co-founder U.S. president title from official leadership roster.
Ibex about page states solutions enhance diagnostic quality, accelerate turnaround, and increase physician confidence for breast, prostate, lung, and gastric cancers across H&E and IHC workflows — clinical outcomes Mossel’s U.S. commercial leadership must deliver to maintain widest pathology AI deployment claim on ibex-ai.com. Biopharma IHC quantification offering extends Mossel’s revenue beyond clinical diagnostics into pharmaceutical trial biomarker scoring.
Ibex leadership includes CEO Yair Heller and co-founder CTO Chaim Linhart, PhD, with Mossel as co-founder, president, GM U.S., and board member per about page — governance and operating authority Mossel holds in Ibex’s primary U.S. growth market outside Israel headquarters established 2016.